Skip to content
Screener

Net Change in Cash at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$417.1M+268%
Jade Biosciences logo
Jade BiosciencesJBIO
-$33.35M-71.4%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$240.37M-540%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
-$6.28M-353%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
13,050,000%-102,425,000pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$11.36M-1,124%

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.89B+284%
Enterprise value$5.82B+277%
P/S11×+6.4×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001438533-26-000042
Line itemFor the Three Months Ended March 31, 2026For the Three Months Ended March 31, 2025
Cash Flows From Financing Activities:
Payment of guaranteed minimum royalty(525)(525)
Proceeds from exercise of stock options4,7294,243
Net cash provided by financing activities4,2043,718
Effect of exchange rate changes on cash(60)548
Net (decrease) increase in cash and cash equivalents(14,673)3,362
Cash and cash equivalents, beginning of year93,03558,535
Cash and cash equivalents, end of period$78,362$61,897

Item 1. Financial Statements

FAQ

What is Travere Therapeutics, Inc.'s net change in cash?
Travere Therapeutics, Inc. (TVTX) reported net change in cash of -$14.67M in Q1 2026.
How has Travere Therapeutics, Inc.'s net change in cash changed year-over-year?
Travere Therapeutics, Inc.'s net change in cash decreased by 536.4% year-over-year, from $3.36M to -$14.67M.
What is the long-term trend for Travere Therapeutics, Inc.'s net change in cash?
Over 3 years (2021 to 2024), Travere Therapeutics, Inc.'s net change in cash has grown at a -83.6% compound annual growth rate (CAGR), from $80.98M to $359K.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Travere Therapeutics, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude